<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092402</url>
  </required_header>
  <id_info>
    <org_study_id>2013/180</org_study_id>
    <nct_id>NCT02092402</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome</brief_title>
  <official_title>Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of fecal microbiota transplantation
      (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <arm_group>
    <arm_group_label>Fecal transplantation of own stool</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Autologous fecal transplantation (own stool)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal transplantation (stool from donor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic fecal transplantation (from donor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal transplantation</intervention_name>
    <arm_group_label>Fecal transplantation of own stool</arm_group_label>
    <arm_group_label>Fecal transplantation (stool from donor)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for patients

          1. Signed informed consent

          2. Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or
             discomfort for at least 2 days a week in the last 12 weeks

          3. Age: 18-65 years

        Exclusion criteria for patients

          1. High proportion of butyrate-producing microbiota in fecal samples

          2. Known organic gastrointestinal disease (e.g. IBD)

          3. Previous complicated gastrointestinal surgery

          4. Non-gastrointestinal malignancy

          5. Dementia, severe depression, major psychiatric disorder, or other incapacity for
             adequate cooperation

          6. Females who are pregnant or breast-feeding

          7. Severe endometriosis

          8. Antimicrobial treatment 4 weeks prior to first screening visit

          9. Antimicrobial prophylaxis (eg. acne, urinary tract infection)

         10. Regular consumption of probiotic products 4 weeks prior to randomization

         11. Recently (within the last 3 months) diagnosed lactose intolerance

         12. Celiac disease

         13. Abuse of alcohol or drugs

         14. Any clinically significant disease/condition which in the investigator's opinion could
             interfere with the results of the trial

        Inclusion criteria for donors

          1. Signed informed consent

          2. High-butyrate producing microbiota in fecal samples

          3. Age: 18-65 years

        Exclusion criteria for donors

          1. Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or
             constipation)

          2. Gastrointestinal malignancy or polyposis

          3. History of major gastrointestinal surgery (e.g. gastric bypass)

          4. Eosinophilic disorders of the gastrointestinal tract

          5. Current communicable disease (e.g. upper respiratory tract infection)

          6. Known or high risk of infectious diseases such as HIV, hepatitis A, B or C

          7. Non-gastrointestinal malignancy

          8. Dementia, severe depression, major psychiatric disorder, or other incapacity for
             adequate cooperation

          9. Comorbidities such as metabolic syndrome, autoimmune diseases, allergies

         10. Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia)

         11. Severe or morbid obesity

         12. Use of immunosuppressive or chemotherapy agents

         13. Antimicrobial treatment or prophylaxis within the last 6 months

         14. Females who are pregnant or breast-feeding

         15. Known clinically significant abnormal laboratory values

         16. Participation in high-risk sexual behaviors

         17. Abuse of alcohol or drugs

         18. Tattoo or body piercing within the last 6 months

         19. Travel to areas with endemic diarrhea during the last 3 months

         20. Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen,
             cryptosporidium antigen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Brummer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Örebro, Department of Gastroenterology and Örebro University, School of Health and Medical Sciences, Faculty of Medicine and Health, Örebro, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Fecal transplantation</keyword>
  <keyword>microbiota transplantation</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

